Company expects 2H 2026 SG&A and R&D expenses of $114 mln to $126 mln
Company anticipates path to cash flow breakeven by end of 2027
Interim Phase 2b data for CSU program expected in Q1 2027
Overview
US biopharma firm's Q2 neffy net product revenue rose, U.S. epinephrine market share doubled yr/yr
Company posted Q2 net loss of $62.3 mln, with higher operating expenses from media and sales expansion
Operating expenses to be reduced in 2H 2026 as focus shifts to targeted provider engagement
Result Drivers
Targeted provider engagement - Co said shift from broad consumer marketing to targeted high-volume prescriber engagement supported neffy market share growth
Sales force expansion - Co completed expansion of field sales organization, focusing efforts on highest-value prescribers
Increased prescriber base - Over 16,000 unique prescribers in Q2, nearly threefold increase yr/yr
Analyst coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
SPRY•
